For the past 70 years, schizophrenia treatments all targeted the same chemical: dopamine. While that works for some, it causes brutal side effects for others. An antipsychotic drug approved last month by the FDA changes that. It triggers muscarinic receptors instead of dopamine receptors. The drug is the result of a chance scientific finding ... from a study that wasn't even focused on schizophrenia. Host Emily Kwong and NPR pharmaceutical correspondent Sydney Lupkin dive into where the drug originated, how it works and what it might shift for people with schizophrenia.Read more of Sydney's reporting.Curious about other drug treatments in the news? Email us at [email protected] and we might cover your topic on a future episode! Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Short Wave
Transcribed and ready to explore now
Parasites Have Haunted Us For Millions Of Years
24 Oct 2025
Short Wave
Migrating Birds Have a Big, Clear Problem
22 Oct 2025
Short Wave
We Have the Cure. Why is Tuberculosis Still Around?
21 Oct 2025
Short Wave
Should Scientists Genetically Engineer Wild Species?
20 Oct 2025
Short Wave
Science Says Quitting Smoking At Any Age Is Good For The Brain
17 Oct 2025
Short Wave
What Happens When You're Under Anesthesia?
15 Oct 2025
Short Wave